- Gilead Sciences (NASDAQ:GILD +0.8%) Q3 results ($M): Total Revenues: 6,041.8 (+117.1%); Sovaldi Sales: 2,796,1; Total Antiviral Sales: 5,544.5 (+138.3%); Other Product Sales: 423.7 (+10.6%).
- COGS: 987.3 (+44.8%); R&D Expense: 630.5 (+29.1%); SG&A Expense: 944.8 (+150.7%); Net Income: 2,724.3 (+245.5%); EPS: 1.67 (+255.3%).
- Gross Profit: 5,054.5 (+140.6%); COGS: 16.3% (-33.3%); Gross Margin: 83.7% (+10.8%); Operating Profit: 3,479.2 (+181.6%); Operating Earnings Yield: 57.6% (+29.7%); Net Earnings Yield: 45.1% (+59.1%); Quick Assets: 7,691.7 (+179.1%).
-
2014 Guidance: Net product sales: $22B - 23B from $21B - 23B; non-GAAP gross margin: 86 - 88% from 85 - 88%; R&D expense: $2.3B - 2.4B (unch); SG&A expense: $2.7B - 2.8B from $2.3B - 2.4B; effective tax rate: 17.5 - 19.5% from 17.5 - 20.5%.